Heterogeneity of SLE
Risk of organ damage
Disease Outcomes
Immune Dysregulation
Role of Cytokines
Significance of IFN-1
View AstraZeneca’s Commitment to SLE
Connect With a Medical Science Liaison
Expert On-Demand
This website is intended to help healthcare professionals practicing in Egypt find and access scientifically balanced, evidence-based, and peer-led information and professional resources in support of the early diagnosis and timely referral of patients with lupus. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.
The estimated prevalence of SLE in the US is 72.8 per 100,000 person-years2 and in Egypt is 6.1/100,000 population.3 SLE has a strong genetic component4,5 SLE affects a diverse patient population, encompassing a wide range of ethnicities, with higher prevalence rates in women GC, glucocorticoid; HRQoL, health-related quality of life; IFN-1, type 1 interferon; LE, lupus erythematosus; SLE, systemic lupus erythematosus; LLDAS: Lupus Low Disease Activity State; HDAS: High disease activity status.
References:
1. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. 2. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991-996. 3. Gheita, T.A. et al. (2021) ‘Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint’, Lupus, p. 096120332110142. doi:10.1177/09612033211014253. 4. Martín, J. and David, F. (2019) Genetics of Rare Autoimmune Diseases. Switzerland: Springer. 5. Kuo, C.-F. et al. (2015) ‘Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families’, JAMA Internal Medicine, 175(9), p. 1518. doi:10.1001/jamainternmed.2015.3528.
The information on this website is provided by AstraZeneca for educational purposes only and is intended for non-UK and non-US Healthcare Professionals only. It should not be used for diagnosing or treating a health problem or disease. This information is intended for Healthcare Professionals only.
EDA Notification No : WF0022OA6344/052026
Invalidation Date : 25/08/2026
Promomat Code : EG-9767
Promomat Expiration Date : 5/21/2027
